Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 4Carcinoma, Hepatocellular 3Triple Negative Breast Neoplasms 2Sarcoma 2Wilms Tumor 1Urinary Bladder Neoplasms 1Upper Tract Urothelial Carcinoma 1Subcutaneous panniculitis-like T-cell lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Breast Cancer Organoids 1

Interventions

Ifosfamide 30Methotrexate 29Doxorubicin 26Cyclophosphamide 24Cisplatin 22Filgrastim 18Etoposide 17Gemcitabine 16Leucovorin 14Magnetic Resonance Spectroscopy 11Temozolomide 10Specimen Handling 10cabozantinib 9apatinib 9X-Rays 9Carboplatin 9fludarabine 8Radiotherapy 8Nivolumab 8Neoadjuvant Therapy 8Irinotecan 8Granulocyte Colony-Stimulating Factor 8Drug Therapy 8Docetaxel 8Zoledronic Acid 7Vincristine 7Sirolimus 7Phantoms, Imaging 7Biopsy 7mifamurtide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × pirarubicin × Clear all
NCT06714383 2024-12-03

Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

Peking University People's Hospital

Phase 2 Recruiting
50 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡